2016
DOI: 10.1016/j.jaci.2016.02.033
|View full text |Cite
|
Sign up to set email alerts
|

IL-1β enhances inflammatory T H 2 differentiation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
24
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(26 citation statements)
references
References 10 publications
2
24
0
Order By: Relevance
“…40,41 At the moment, human studies with regard to anti-IL-33 are ongoing 42,43 and still have to prove their beneficial effect in asthmatic patients. As decreased IL-1β levels were observed in DEP+HDM-exposed mice that were prophylactically treated with r-sST2, but not therapeutically, this could be a potential mechanism of the observed discrepancy in inflammatory airway responses since IL-1β was previously found to be involved in type 2 promoting responses.…”
Section: Therapeutic R-sst2 Administration Does Not Modulate the Dementioning
confidence: 99%
See 1 more Smart Citation
“…40,41 At the moment, human studies with regard to anti-IL-33 are ongoing 42,43 and still have to prove their beneficial effect in asthmatic patients. As decreased IL-1β levels were observed in DEP+HDM-exposed mice that were prophylactically treated with r-sST2, but not therapeutically, this could be a potential mechanism of the observed discrepancy in inflammatory airway responses since IL-1β was previously found to be involved in type 2 promoting responses.…”
Section: Therapeutic R-sst2 Administration Does Not Modulate the Dementioning
confidence: 99%
“…As decreased IL-1β levels were observed in DEP+HDM-exposed mice that were prophylactically treated with r-sST2, but not therapeutically, this could be a potential mechanism of the observed discrepancy in inflammatory airway responses since IL-1β was previously found to be involved in type 2 promoting responses. 40,41 At the moment, human studies with regard to anti-IL-33 are ongoing 42,43 and still have to prove their beneficial effect in asthmatic patients. Moreover, it would be interesting to examine the functional role of other epithelial type 2-promoting cytokines, for example, IL-25…”
Section: Therapeutic R-sst2 Administration Does Not Modulate the Dementioning
confidence: 99%
“…This Th2/Th17 phenotype is in line with the cytokines detected here. While IL-23 is obligatory for survival of Th17 cells 34 , IL-1β has been reported as an important factor of the Th2 immune response 35 . In the context of allergy, Dectin-signaling may therefore promote the present type 2-response while fueling the fungus-associated Th17 axis in parallel.…”
Section: Discussionmentioning
confidence: 99%
“…Regarding the "reverse mechanism", soluble inflammatory cytokines released into the TME by tumor-infiltrating immune cells could modulate CSC activities as well. For instance, the soluble factor IL-1 promoted Th-1 to Th-2 differentiation, thus contributing to the inhibition of antitumor immunity [67,68]. In particular, IL-1β stimulated the expression of the CSC-related marker ZEB1, induced resistance to chemotherapy, and increased sphere-forming efficiency in colon cancer cells, thus supporting a role for IL-1β in promoting CSC self-renewal and EMT [69].…”
Section: Immunomodulatory Molecules Stimulating Tumor Stemness: the Dmentioning
confidence: 94%